The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003
PET scanning poorly predicts response to pre-operative chemotherapy in non-small cell lung cancer Source: ISSN=ISSN 1810-6838, ISBN=, page=54 Year: 2004
Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004
An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed (Pem) for advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018
Correlatin between PET scan and cytokine in non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
Prognostic impact of FDG-PET in recurrence of surgically treated non-small cell lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005
Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors Year: 2008
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011
A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011
Systematic review of the effect of chemotherapy on quality of life (QoL) and symptom control in patients with non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Lung cancer treatment Year: 2006
Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002